Roflumilast is an oral phosphodiesterase-4 selective inhibitor with anti-inflammatory action targeting the systemic inflammation associated with chronic obstructive pulmonary disease (COPD). Several studies have recently evaluated the clinical efficacy and safety of roflumilast in the treatment of COPD, showing its capacity in reducing exacerbations and hospital admissions in patients at risk of frequent and severe exacerbations despite conventional inhaled therapy with inhaled corticosteroids, long-acting beta-agonists, and long-acting muscarinic antagonist.[1,2]

Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease

Dragonieri S.;Quaranta V.;Carratu P.;Carpagnano G.;D'Alba G.;Resta O.
2016

Abstract

Roflumilast is an oral phosphodiesterase-4 selective inhibitor with anti-inflammatory action targeting the systemic inflammation associated with chronic obstructive pulmonary disease (COPD). Several studies have recently evaluated the clinical efficacy and safety of roflumilast in the treatment of COPD, showing its capacity in reducing exacerbations and hospital admissions in patients at risk of frequent and severe exacerbations despite conventional inhaled therapy with inhaled corticosteroids, long-acting beta-agonists, and long-acting muscarinic antagonist.[1,2]
File in questo prodotto:
File Dimensione Formato  
LungIndia335579-6509506_180455.pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 583.93 kB
Formato Adobe PDF
583.93 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11586/296627
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact